Casma Therapeutics Is A Biotechnology Company Based In Cambridgemafounded In 2018The Company Specializes In Reprogramming The Autophagy Pathway To Develop Innovative Therapeutics Aimed At Eliminating Disease Causing Cellular Componentstheir Core Technologythe Phlyta C Platformtargets The Autophagy Lysosomal System To Degrade Harmful Elements Within Cellsaddressing Diseases That Traditional Therapies Have Struggled To Treat Casma S Research Focuses On The Autophagy Mediated Degradation Of Targets Associated With Neurodegenerative Disorderscancerand Lysosomal Storage Disordersthe Company Has Secured Significant Fundingincluding A $46 Million Series C Round In 2022With Participation From Notable Investors Like Amgen Ventures And Astellaswith A Mission To Restore Health By Eliminating Cellular Damagecasma Emphasizes Scientific Innovation And Strategic Collaborations To Expand Treatment Options For Challenging Diseases
